Avitar, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVTI research report →
About the company
Avitar, Inc. , through its subsidiaries, designs, develops, manufactures, and markets diagnostic test products and proprietary hydrophilic polyurethane foam disposables for medical, diagnostics, dental, and consumer applications in the United States. It offers ORALscreen 4 and ORALscreen DRUGOMETER, the oral fluid-based onsite assay systems, for detecting drugs of abuse, such as opiates, including heroin, morphine, codeine, and synthetic opiates comprising oxycocone-oxycontin, percoset, and hydrocodone-vicodin; cocaine, such as crack; marijuana; and methamphetamines, including meth and ecstasy.
- CEO
- Cory H. Gelmon
- IPO
- 1994
- Employees
- 36
- HQ
- Calgary, MA, CA
Price Chart
- Market Cap
- $1.38K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -3.10
- Div Yield
- 0.00%
- Gross Margin
- 26.94%
- Op Margin
- 87.98%
- Net Margin
- -72.75%
- ROE
- 25.07%
- ROIC
- -203.85%
- Revenue
- $3.11M · -36.93%
- Net Income
- $-2,259,629 · 38.98%
- EPS
- $-0.11 · 85.53%
- Op Income
- $2.73M
- FCF YoY
- 36.42%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -15.30
- Avg Volume
- 22.33K
Get TickerSpark's AI analysis on AVTI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our AVTI coverage
Recent articles, reports, and earnings notes.
No research on AVTI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVTI report →Similar companies
Peers in the same neighborhood.